Clinical trials: Multicentric Breast Carcinoma
Breast Cancer
Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer
The previous reported phase I study allows us to prospectively define the optimal total dose in different metastatic locations (88).
- Trial name
- STEREO-SEIN (NCT02089100)
- Testing
- stereotactic body radiation therapy, Systemic treatment
- Where
- 18 sites in France
- Volunteers
- 154 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Triple Negative Breast Cancer
Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)
Previous studies in Western country show that triple-negative breast cancer has aggressive clinical and pathological features compared with non-triple negative breast cancer, including onset at a young age, advanced clinical…
- Trial name
- NCT01216111
- Testing
- Paclitaxel Cisplatin, fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)
- Volunteers
- 647 people
- Sponsor
- Fudan University
Endometrial Cancer, Endometrial Hyperplasia With Atypia
Endometrial Changes in Breast Cancer Women.
This is a prospective observational multicentric study. The aim is to evaluate the incidence of endometrial cancer and endometrial atypical hyperplasia in patients with previous breast cancer, treated with different adjuvant…
- Conditions
- Endometrial Cancer, Endometrial Hyperplasia With Atypia, Breast Cancer, TAM
- Trial name
- NCT05717634
- Testing
- Hysteroscopy
- Where
- Italy
- Volunteers
- 829 people, healthy volunteers welcome
- Sponsor
- Regina Elena Cancer Institute
Metastatic Breast Cancer
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
This study is a randomized, open-label, multicentric, phase III trial conducted in patients receiving aromatase inhibitor and palbociclib as first line therapy for estrogen receptor (ER)-positive HER2-negative metastatic breast…
- Trial name
- PADA-1 (NCT03079011)
- Testing
- Palbociclib 125mg, Aromatase Inhibitors, Fulvestrant Injectable Product
- Where
- 82 sites in France
- Volunteers
- 1,017 people
- Sponsor
- UNICANCER
Breast Cancer
Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging
In order to explain the value of adding CESM into the clinical pathway, and also to obtain the relevant clinical data to support future update of clinical guideline, we plan to evaluate the detection rate of CESM for additional…
- Trial name
- COMBO-I (NCT06475066)
- Testing
- contrast-enhanced spectral mammography
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Breast Cancer Diagnosis, Breast Cancer Prevention
Contrast Enhanced Mammography in the Evaluation of Cancer of Unknown Primary Syndrome
This study aims to evaluate the role of Contrast-Enhanced Mammography (CEM) in identifying the primary tumor site in patients presenting with Cancer of Unknown Primary (CUP) syndrome.
- Trial name
- CEM_CUP_syndr (NCT06843096)
- Testing
- Contrast-Enhanced Mammography (CEM)
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- Graziella di Grezia
Metastatic Breast Cancer
Retroprospective Real Life Observatory of Eribulin
The objective of this observatory is to evaluate the effecacy of Eribulin in patients with metastatic breast cancer on a recent prescription period.
- Trial name
- ReProLine (NCT02393287)
- Testing
- Eribulin (ReProLine)
- Where
- 13 sites in France
- Volunteers
- 753 people
- Sponsor
- Institut Cancerologie de l'Ouest
Breast Cancer
Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen
This is a prospective, Phase IV, multi-center, single arm, open-label, interventional study to evaluate the safety of trastuzumab for the treatment of human epidermal growth factor receptor 2 protein (HER2)-positive node positive…
- Trial name
- NCT02419742
- Testing
- Carboplatin, Cyclophosphamide, Docetaxel
- Where
- 6 sites in India
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer
Neoadjuvant chemotherapy (NAC) is increasingly used for early-stage operable breast cancer. Response of breast cancer to NAC is correlated with survival: patients who obtain greatest survival advantage are those who attain…
- Trial name
- BERNAQ (NCT02365805)
- Testing
- Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel, Epirubicin + Cisplatin + Fluorouracil, Docetaxel + Ciclofosfamide
- Where
- 7 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Breast Cancer, Breast Cancer Invasive
Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer
Breast-conserving surgery (BCS) has become the standard-of-care for surgical management of the majority of women with early-stage breast cancer.
- Conditions
- Breast Cancer, Breast Cancer Invasive, Breast Cancer in Situ
- Trial name
- BrIMA (NCT04999917)
- Testing
- high-resolution PET-CT specimen imaging.
- Where
- Belgium
- Volunteers
- 206 people
- Sponsor
- XEOS Medical
Safety of Breast Coservative Multicenteric Breast Cancer, Breast Neoplasms
Oncological Safety of Oncoplastic Breast Surgery in Multicentric Breast Cancer
The purpose of the study is to evaluate Oncological safety of oncoplastic breast surgery in multicentric breast cancer
- Conditions
- Safety of Breast Coservative Multicenteric Breast Cancer, Breast Neoplasms, Breast Cancer, Multicentric
- Trial name
- NCT06926335
- Testing
- Breast consevative surgery
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Breast Cancer
A Clinical Investigation to Confirm the Ability of MammoWave in Breast Lesions Detection
This is a multicentric, single arm, prospective, stratified by breast density clinical investigation to confirm the ability of the microwave mammogram 'MammoWave' to detect breast lesions.
- Trial name
- NCT05300464
- Testing
- Clinical investigation medical device class IIa marked CE
- Where
- 4 sites in Italy, Spain
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Umbria Bioengineering Technologies
Breast Cancer Screening
Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography
This study is a randomized, multicenter, multivendor, controlled, diagnostic superiority trial to compare digital breast tomosynthesis plus synthesized 2D mammograms (DBT+s2D) versus standard 2D full-field digital mammography…
- Trial name
- TOSYMA (NCT03377036)
- Testing
- DBT+s2D, 2D-FFDM
- Where
- 21 sites in Germany
- Volunteers
- 99,689 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Breast Cancer
ROLL Versus Magnetic Seed for Preoperative Localization of Non-palpable Breast Lesion: Comparison Between Techniques.
Nowadays, Breast Conservative Surgery (BCS) is the standard of care for patients affected by early breast lesions. Screening programmes led to an increase of impalpable breast lesion detection rates.
- Trial name
- SEED01 (NCT05942092)
- Testing
- Breast conserving surgery
- Where
- Italy
- Volunteers
- 1,400 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Women's Health: Neoplasm of Breast
A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer Detection
This is an open, multicentric, interventional, prospective, non-randomized clinical investigation. The first aim of the study is to confirm that MammoWave reaches sensitivity>75% and specificity>90% in breast cancer (BC)…
- Trial name
- NCT06291896
- Testing
- MammoWave
- Where
- 10 sites in Italy, Poland and 3 more
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Umbria Bioengineering Technologies
Breast Carcinoma, Breast Reconstruction
Prepectoral and Subpectoral Implant-based Breast Reconstruction
Breast cancer is one of the main malignant tumors threatening women's lives. In recent years, the increasing demand for reconstruction of breast cancer patients in China has made the proportion of breast reconstruction increase…
- Trial name
- NCT04688697
- Testing
- prepectoral implant-based reconstruction, subpectoral implant-based reconstruction
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Breast Cancer
Pre-pectoral Breast Reconstruction PART 2
The rationale for present trial conception and design moves forward from the assumption that a subcutaneous, pre-pectoral reconstruction by means of soft tissue replacement devices is feasible, safe and giving rewarding results…
- Trial name
- PreBRec (NCT02831426)
- Testing
- Two-stage with Acellular Dermal Matrix (CELLIS® Breast), Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)
- Where
- United Kingdom
- Volunteers
- 86 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Breast Cancer
Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.
- Trial name
- BONBIS (NCT00907868)
- Testing
- partial breast irradiation, whole breast irradiation
- Where
- France
- Volunteers
- 2,004 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Triple Negative Breast Cancer, Metastatic Breast Cancer
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
ISIdE is an European, multicentric study that aims to assess the efficacy of Sacituzumab Govitecan (SG) in locally advanced or metastatic triple-negative breast cancer where the disease has progressed despite chemotherapy or…
- Trial name
- ISIdE (NCT05552001)
- Testing
- Sacituzumab govitecan
- Where
- France
- Volunteers
- 96 people
- Sponsor
- UNICANCER
Breast Cancer Model, Effects of Chemotherapy
PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer
This study aims to explore new PERS prediction model can improve the pathological complete response rate of neoadjuvant chemotherapy of breast cancer and disease-free survival.
- Conditions
- Breast Cancer Model, Effects of Chemotherapy, Breast Cancer
- Trial name
- PERS (NCT03006614)
- Testing
- NVB, EPI, DDP
- Where
- China
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Shi Yanxia